Halozyme
An open-label multiple-dose, 52-week study to evaluate the safety, pharmacokinetics, and efficacy of XYOSTED.
Status: Actively recruiting
Contact: ECRU@childrens.harvard.edu
Clinical trials
An open-label multiple-dose, 52-week study to evaluate the safety, pharmacokinetics, and efficacy of XYOSTED.
Status: Actively recruiting
Contact: ECRU@childrens.harvard.edu